TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the plasma concentration-time curve (AUC0-t) of lumateperone and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Myocardial enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time-to-QOL Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) After Single Dose Suvorexant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in knowledge, beliefs, and actions regarding children's mental health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent of bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in serum estradiol (E2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: long-term glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant fear of childbirth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Linear measurements outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Cardiac Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain during IUD placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined-testing uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response conversion rate (PD/SD to PR and CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biliary ductal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decline in FEV1 ≥ 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline Hamilton depression rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serological status/rate of past infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety (adverse effects)
Endpoint domain: Adverse events/effects
Primary endpoint: ACR Pediatric Response Level (ACRPRL) 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma non-transferrin-bound iron (NTBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance of the BCI-system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Had Residual Cancer Found
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of LUM Imaging System on Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of LUM Imaging System Detection on Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change from baseline in visual evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of treatment without calcineurin inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects of treatment without calcineurin inhibitors
Endpoint domain: Adverse events/effects
Primary endpoint: satisfaction with contraceptive method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infusion rate reduction of propofol and remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CD4+ T cell subsets in blood and colonic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in level of Type 1 collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of ABT-450
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in myocardial glycogen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MDS-UPDRS part III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Days until readiness-to-discharge criteria are met
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency and severity of freezing of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intrarater and interrater consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-hour steady-state plasma concentration of fluticasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of sustained ventricular tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients experiencing adverse events, coded by body system
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ESRS dyskinesia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Left Ventricular End-diastolic volume (LVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular End-systolic volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Q-tip scores (vaginal pain assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of total time blood glucose in range 70-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: post treatment spontaneous and provoked pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Positive Urine Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Maximum Days Abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Showing Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic adequacy of the liver biopsy specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure generated in ICV during Cecal distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma Concentration of ARQ-151 Cream 0.3%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of the Roflumilast Major N-oxide Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Application Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of new COVID-19 cases
Endpoint domain: Mortality/survival
Primary endpoint: Mortality rate secondary to COVID-19 cases
Endpoint domain: Mortality/survival
Primary endpoint: Intensive Care Unit (ICU) admission rate secondary to COVID-19 cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nociceptive flexion reflex threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in temporal summation of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical characteristics of retinovascular structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of positive H-score of HE4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of the telesurgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Spacer Volume Half Life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Talimogene Laherparepvec Detected in Blood and Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Positive for Anti-herpes Simplex Virus-1 (HSV-1) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean score of sum of 2 blinded observers POSAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Plasma Concentration of Nicotine/Cotinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Score of the Short Version of the Questionnaire of Smoking Urges (QSU-brief)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Live delivery rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinical global Impression-Severity of illness (CGI-S) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical global Impression-Improvement (CGI-I) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clotted dialyzers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected International Normalization Ratio (INR) in neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of lung biopsy specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline plasma endotoxin concentration at 10 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline plasma zonulin concentration at 10 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of serum antibody induced by vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportion of women with inadequate rate of weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability determined by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood concentrations of GSK1034702
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of households enrolled in an ACA plan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of correct answers
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Appendix identification rate on ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With an Episode of Clinically-suspected and Biopsy-proven Acute Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Covid-19 Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in edema amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) rate at month 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Conjugated Bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Average Change in Alkaline Phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Average Improvement in AST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Average Improvement in ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Subjects With Expression of Tumor Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects With a Pre-identified Gene Signature (GS) to the recMAGE-A3 Cancer Immunotherapeutic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients Responding to Treatment, by Best Clinical Response Type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI findings of encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurodevelopment at 2 years of age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Toronto Western Spasmodic Torticollis Rating Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burke-Fahn-Marsden Dystonia Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Middle Ear exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aesthetic evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Exposure to environmental tobacco smoke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pursuance of Surgical Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Level of asynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Terminal Hairs in the Target Area of the Scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Vellus Hairs in the Target Area of the Scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Total Hairs in the Target Area of the Scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Experiencing Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Experiencing Adverse Events Unrelated to Device
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Concordance of fMCG and Postnatal ECG for Diagnosis of Long QT Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Subjects Experiencing Adverse Events Related to Device
Endpoint domain: Adverse events/effects
Primary endpoint: Functional Connectivity of Amygdala with the Prefrontal Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative abdominal and/or shoulder VAS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in average pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CH24H Brain Enzyme Occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiotoxicity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxidative stress and inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With hSBA Titers ≥1:4 Against Meningococcal Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean hSBA Titers Directed Against Meningococcal Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration Against Meningococcal 287-953 Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: 25-Hydroxyvitamin D Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of 99mTc ThromboView®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Specificity of 99mTc ThromboView®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Visual Analogical Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coagulation factor VIII levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Responder sub-population outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of the adapted physical activity program (ratio 1)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: feasibility of the adapted physical activity program (ratio 2)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in PTSD Checklist total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in diagnosis of PTSD on the MINI Neuropsychiatric Interview
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Addiction Severity Index alcohol composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrient quality index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients That Achieved a Complete Response or a Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients That Achieved a Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent time in euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Behavior Assessment Scale for Children (BASC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Swanson, Kotkin, Agler, M-Flynn & Pelham Rating Scale (SKAMP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success Rate of Stem Cell Mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean frequency of micturitions per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Rhabdomyolysis (RML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fracture Injury Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Non-Contact Injury Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-Contact Muscle Injury Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tendon Injury Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ligament Injury Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Apophysitis Injury Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in plasma lipides/lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ciprofloxacin pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to liver transplantation or death
Endpoint domain: Mortality/survival
Primary endpoint: Patient Satisfaction With Cancer Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Care Partner Satisfaction With Cancer Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of Post-Traumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in narcotics usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time spent out of bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Skin hydration values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Skin pH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Pins Inserted Into a Virtual Voodoo Doll After 48 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep pattern
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement in overall sensory for motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Care Transition Measure
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages Of Subjects With hSBA≥ 1:5 Titers Against N Meningitidis Serogroup B Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes